Regenxbio Enters Settlement And Release Agreement With GlaxoSmithKline On March 18, 2026; To Pay $10.0M To GlaxoSmithKline For Alleged Underpayment Of Sublicense Fees; Settlement Agreement Includes Mutual Releases Of Past And Certain Future Claims; To Continue To Pay GSK Amounts Received From Sublicensees Pursuant To Existing Sublicense Agreements